Alongside the release of abstracts related to the American Society of Hematology meeting next month in San Diego, and as part of the firm’s third-quarter update, Beam Therapeutics Inc. disclosed that ...
Karolinska Development AB has announced that its portfolio company Dilaforette AB has enrolled the first patient in a clinical Phase II study with sevuparin in patients with sickle-cell disease (SCD).
Beam Therapeutics Inc. disclosed that one patient died in the phase I/II trial testing BEAM-101 in sickle cell disease (SCD), though the case of respiratory failure was determined by the investigator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results